Senseonics‘ (NYSE:SENS) said today that it inked a deal to integrate glucose data from its Eversense continuous glucose monitoring system into Beta Bionics‘ investigational iLet bionic pancreas.

According to the terms of the development agreement, Beta Bionics and Senseonics will work together to combine the two systems in the hopes of driving insulin and glucagon dosing with real-time data from the Eversense monitor.

Senseonics’ long-term, implantable continuous glucose monitor is designed to measure interstitial fluid glucose levels and transmit the data to a user’s smartphone. Beta Bionics’ dual-chamber bionic pancreas is slated to use glucose data to autonomously adjust insulin and glucagon dosing for patients with diabetes.

“We are very excited to partner with Beta Bionics to integrate our long-term glucose sensor with the bionic pancreas system,” Senseonics president & CEO Tim Goodnow said in prepared remarks. “The combination of these two technologies could create a unique option for increased simplicity, convenience and confidence in diabetes management.”

“Senseonics has generated impressive clinical data demonstrating the remarkable accuracy of their Eversense CGM system and providing a categorically different CGM alternative for people with diabetes,” Ed Damiano, president & CEO of Beta Bionics, added. “We are excited to partner with Senseonics to help make the iLet Bionic Pancreas system a platform of choice for people with diabetes – one that will ultimately allow people to choose between multiple CGMs, to choose between multiple insulin types, and to choose glucagon.”

Earlier this year, an FDA advisory panel voted 8-0 to recommend approval for Senseonics’ implantable CGM. The company is still awaiting the FDA’s final decision regarding U.S. clearance.